| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review |
| 28 Oct 2026 | 10-Q |
| 30 Sep 2026 |
8-K: Other Events
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | SCHEDULE 13G |
| 31 Jul 2026 |
Form 4: Mohideen Pharis, Chief Medical Officer
Sold 464 shares ($1.25K) |
| 27 Jul 2026 | S-3ASR |
| 16 Jul 2026 |
8-K: Results of Operations and Financial Condition
Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026 |
| 16 Jul 2026 | 10-Q |
| 29 Jun 2026 |
8-K: Other Events
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
| 04 Jun 2026 | S-8 |
| 03 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
The Company was incorporated in the form of a French Limited Company (Société Anonyme) with a Board of Directors. |
| 15 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | SCHEDULE 13G/A |
| 12 May 2026 | SCHEDULE 13G/A |
| 11 May 2026 | ARS |
Loading...